{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:29:57Z","timestamp":1786422597412,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Breakthrough invasive fungal infections (IFIs) remain a major challenge in children with acute leukemia, even under mold-active prophylaxis. Data on the epidemiology, risk factors and outcomes of breakthrough IFIs in pediatric populations are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study included patients 0\u201318 years of age with acute leukemia who were diagnosed and followed at the Pediatric Hematology Clinic of Ankara Bilkent City Hospital between February 2019 and December 2023. We conducted a retrospective cohort study of 147 pediatric patients with acute leukemia who received mold-active antifungal prophylaxis. Demographic and clinical features, antifungal prophylactic regimens, infection classifications (proven, probable and possible), microbiological and radiological findings and outcomes were analyzed. IFIs were defined and classified according to the EORTC\/MSGERC 2020 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 147 patients (43.5% female, 56.5% male; mean age 9.5 years), 68.0% had acute lymphoblastic leukemia and 32.0% had acute myeloid leukemia. All patients received mold-active prophylaxis, most commonly voriconazole (84.4%, n = 124). Overall, 29.3% (n = 43) of patients developed an IFI. Among those with IFI, 81.4% (n = 35) were classified as possible, 11.6% (n = 5) as probable and 7.0% (n = 3) as proven. Infection incidence was similar between acute lymphoblastic leukemia (29.0%) and acute myeloid leukemia (31.2%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.779). A total of 7 patients died because of the fungal infections, yielding a case-fatality rate of 16.3% (7\/43) among patients with IFI. Mortality varied markedly by diagnostic certainty: 5.7% in possible, 60.0% in probable and 66.7% in proven IFIs. Proven\/probable infections were mainly due to\n                      <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic>\n                      spp. The most frequently used therapeutic agents were liposomal amphotericin B (43.2%) and caspofungin (30.9%), alone or in combination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite mold-active antifungal prophylaxis, nearly one-third of pediatric leukemia patients developed IFIs, with high mortality in probable and proven cases. The predominance of breakthrough mold infections underscores the limitations of current prophylactic strategies. Optimized prophylaxis, therapeutic drug monitoring and early diagnostic approaches are urgently needed to reduce the burden of IFIs in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005196","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:00:49Z","timestamp":1772514049000},"page":"783-788","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Breakthrough Invasive Fungal Infections in Pediatric Acute Myeloid and Lymphoblastic Leukemia Receiving Mold-active Prophylaxis"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-1301","authenticated-orcid":false,"given":"Belgin","family":"G\u00fclhan","sequence":"first","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Bilkent Children City Hospital, University of Health Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ankara Bilkent Children City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Arman Bilir","sequence":"additional","affiliation":[{"name":"Pediatric Haematology Department, Ankara Bilkent Children City Hospital, University of Health Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne\u015fe","family":"Yarali","sequence":"additional","affiliation":[{"name":"Pediatric Haematology Department; Ankara Yildirim Beyazit Medicine Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turan","family":"Bayhan","sequence":"additional","affiliation":[{"name":"Pediatric Haematology Department; Ankara Yildirim Beyazit Medicine Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Kanik Y\u00fcksek","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Yildirim Beyazit Medicine Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Erat","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Bilkent Children City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"\u00d6zen","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Bilkent Children City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Yah\u015fi","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Bilkent Children City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice K\u00fcbra","family":"Konca","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Bilkent Children City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcls\u00fcm \u0130clal","family":"Bayhan","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Yildirim Beyazit Medicine Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslinur","family":"\u00d6zkaya Parlakay","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Ankara Yildirim Beyazit Medicine Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namik Ya\u015far","family":"\u00d6zbek","sequence":"additional","affiliation":[{"name":"Pediatric Haematology Department, University of Health Science, Ankara Bilkent Children City Hospital, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"key":"R2-20260811","first-page":"174","article-title":"Antifungal prophylaxis in pediatric patients with hematologic malignancies and hematopoietic cell transplantation recipients.","volume":"9","author":"Lehrnbecher","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s12879-023-08314-9","article-title":"Changing patterns of invasive fungal infections in a pediatric hematology-oncology unit: the rise of breakthrough mold infections.","volume":"23","author":"Calle-Miguel","year":"2023","journal-title":"BMC Infect Dis"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11046-024-00864-z","article-title":"Breakthrough invasive mold infections: current challenges and future directions.","volume":"189","author":"Portillo","year":"2024","journal-title":"Mycopathologia"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC\/MSGERC).","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology.","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"159","DOI":"10.24953\/turkjped.2019.02.002","article-title":"Invasive fungal infection in children with hematologic malignancy.","volume":"61","author":"G\u00fclhan","year":"2019","journal-title":"Turk J Pediatr"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fmicb.2019.00681","article-title":"Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study.","volume":"10","author":"Lehrnbecher","year":"2019","journal-title":"Front Microbiol"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/microorganisms12010145","article-title":"Invasive fungal infections in children with acute leukemia: epidemiology, risk factors, and outcome.","volume":"12","author":"Etzioni","year":"2024","journal-title":"Microorganisms"},{"key":"R10-20260811","first-page":"100947","article-title":"Invasive fungal disease in children with acute leukemia: the impact of antifungal prophylaxis in an Australian multicenter study.","volume":"41","author":"Yeoh","year":"2024","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:00:52Z","timestamp":1786420852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005196","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}